Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
5,853
Sort by:
Liver Cancer (Oncology) - Drugs in Development, 2021
US$ 2,500.00
Liver Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Liver Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Liver Cancer pipeline landscape. The report provides compr...
April 2021
325 pages
Liver X Receptor (LXR) - Drugs in Development, 2021
US$ 3,000.00
Liver X Receptor (LXR) - Drugs in Development, 2021 SUMMARY Liver X Receptor (LXR) - Drugs in Development, 2021 provides in depth analysis on Liver X Receptor (LXR) targeted pipeline therapeutics. The...
April 2021
30 pages
Low-Grade Glioma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Low-Grade Glioma (Oncology) - Drugs in Development, 2021 SUMMARY Low-Grade Glioma (Oncology) - Drugs in Development, 2021 provides an overview of the Low-Grade Glioma pipeline landscape. The report pr...
April 2021
50 pages
Lung Adenocarcinoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Lung Adenocarcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Lung Adenocarcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Lung Adenocarcinoma pipeline landscape. The...
April 2021
100 pages
Lung Disease (Respiratory) - Drugs in Development, 2021
US$ 2,000.00
Lung Disease (Respiratory) - Drugs in Development, 2021 SUMMARY Lung Disease (Respiratory) - Drugs in Development, 2021 provides an overview of the Lung Disease pipeline landscape. The report provides...
April 2021
85 pages
Lung Infections (Respiratory) - Drugs in Development, 2021
US$ 2,000.00
Lung Infections (Respiratory) - Drugs in Development, 2021 SUMMARY Lung Infections (Respiratory) - Drugs in Development, 2021 provides an overview of the Lung Infections pipeline landscape. The report...
April 2021
45 pages
Lung Injury (Respiratory) - Drugs in Development, 2021
US$ 2,000.00
Lung Injury (Respiratory) - Drugs in Development, 2021 SUMMARY Lung Injury (Respiratory) - Drugs in Development, 2021 provides an overview of the Lung Injury pipeline landscape. The report provides co...
April 2021
50 pages
Lupus Nephritis (Immunology) - Drugs in Development, 2021
US$ 2,000.00
Lupus Nephritis (Immunology) - Drugs in Development, 2021 SUMMARY Lupus Nephritis (Immunology) - Drugs in Development, 2021 provides an overview of the Lupus Nephritis pipeline landscape. The report p...
April 2021
90 pages
Malignant Ascites (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Malignant Ascites (Oncology) - Drugs in Development, 2021 SUMMARY Malignant Ascites (Oncology) - Drugs in Development, 2021 provides an overview of the Malignant Ascites pipeline landscape. The report...
April 2021
30 pages
Malignant Glioma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Malignant Glioma (Oncology) - Drugs in Development, 2021 SUMMARY Malignant Glioma (Oncology) - Drugs in Development, 2021 provides an overview of the Malignant Glioma pipeline landscape. The report pr...
April 2021
90 pages
Malignant Neoplasms (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Malignant Neoplasms (Oncology) - Drugs in Development, 2021 SUMMARY Malignant Neoplasms (Oncology) - Drugs in Development, 2021 provides an overview of the Malignant Neoplasms pipeline landscape. The...
April 2021
45 pages
Mast Cell Leukemia (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Mast Cell Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY Mast Cell Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the Mast Cell Leukemia pipeline landscape. The rep...
April 2021
30 pages
Meningioma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Meningioma (Oncology) - Drugs in Development, 2021 SUMMARY Meningioma (Oncology) - Drugs in Development, 2021 provides an overview of the Meningioma pipeline landscape. The report provides comprehensi...
April 2021
55 pages
